TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.
Estelamari Rodriguez, MD, MPH
Articles by Estelamari Rodriguez, MD, MPH
In this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.
In the fourth interview of the series, Dr. Estelamari Rodriguez from the University of Miami Health System considers unmet needs in extensive-stage small cell lung cancer and discusses the role of reactive and proactive approaches to the management of chemotherapy-induced myelosuppression.